ASP3652: Clinical Trials

8 trials of ASP3652, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed. 6 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6
Phase 22Completed 2

Follow ASP3652: new trials by email Literature Review of ASP3652 trials Research Report on ASP3652

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects
ASP3652 - Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652
Phase 1CompletedAstellas Pharma Europe B.V.142012-09-012014-01-13
A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects
ASP3652, Placebo - Pharmacokinetics, Pharmacodynamics
Phase 1CompletedAstellas Pharma Europe B.V.262012-08-012013-03-21
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability
ASP3652 - Pharmacokinetics, Pharmacodynamics
Phase 1CompletedAstellas Pharma Europe B.V.642012-07-012013-10-08
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652
ASP3652 - Healthy Subjects, Pharmacokinetics of ASP3652
Phase 1CompletedAstellas Pharma Europe B.V.62012-07-012014-01-28
A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)
ASP3652, Placebo - Cystitis, Interstitial, Urinary Bladder Disease
Phase 2CompletedAstellas Pharma Europe B.V.2872012-05-312024-11-05
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects
ASP3652, Gemfibrozil, Repaglinide - Drug-Drug Interaction (DDI), Healthy Subjects
Phase 1CompletedAstellas Pharma Europe B.V.482012-04-012013-02-22
A Clinical Study to Investigate the Efficacy, Safety and Pharmacokinetics of ASP3652 in Patients With Chronic Abacterial Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS)
ASP3652, Placebo - Chronic Abacterial Prostatitis, Chronic Pelvic Pain Syndrome
Phase 2CompletedAstellas Pharma Inc2392011-06-012013-03-21
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652
ASP3652, Placebo - Healthy Subjects, Pharmacokinetics of ASP3652
Phase 1CompletedAstellas Pharma Europe B.V.1012009-05-012014-09-18

Conditions studied

Bronchiolitis Obliterans Syndrome (1)  ·  Coitus (1)  ·  Cystitis, Interstitial (1)  ·  Pain (1)  ·  Pelvic Pain (1)  ·  Prostatitis (1)  ·  Urinary Bladder Diseases (1)  ·  Urologic Diseases (1)

Sponsors

Astellas Pharma Europe B.V. (7)  ·  Astellas Pharma Inc (1)

Countries

United Kingdom (4)  ·  Netherlands (3)  ·  Czechia (2)  ·  Germany (2)  ·  Latvia (2)  ·  Lithuania (2)  ·  Poland (2)  ·  Spain (2)  ·  Belgium (1)  ·  Denmark (1)  ·  Portugal (1)  ·  Romania (1)  ·  Russia (1)

Results publications

PMID 32715381, PMID 30178528

NIH funding

2008 (1)